Glycans as vaccine Antigens and Adjuvants: Immunological considerations

Methods in Molecular Biology

Volumn 1331, Issue , 2015, Pages 11-26

  Zimmermann, Stephanie ^a   Lepenies, Bernd ^a  

^a NONE

Author keywords

Adjuvants; C type lectin receptors; Carbohydrate based vaccines; Conjugate vaccines; Glycans; Immunity; Toll like receptors

Indexed keywords

B7 ANTIGEN; C TYPE LECTIN RECEPTOR; CD28 ANTIGEN; CD86 ANTIGEN; GLYCAN; IMMUNOLOGICAL ADJUVANT; LECTIN RECEPTOR; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; VACCINE; ANTIGEN; BACTERIAL VACCINE; POLYSACCHARIDE;

ADAPTIVE IMMUNITY; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; NEISSERIA MENINGITIDIS; SALMONELLA ENTERICA SEROVAR TYPHI; STREPTOCOCCUS PNEUMONIAE; ANTIBODY PRODUCTION; IMMUNITY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PROCEDURES; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODY FORMATION; ANTIGENS; BACTERIAL VACCINES; HUMANS; IMMUNITY; LYMPHOCYTE ACTIVATION; POLYSACCHARIDES; VACCINATION; VACCINES, CONJUGATE;

EID: 84959223142     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-2874-3_2     Document Type: Chapter

References (81)

1. Whitfield C, Trent MS (2014) Biosynthesis and export of bacterial lipopolysaccharides. Annu Rev Biochem 83:99–128
2. Roberts IS (1996) The biochemistry and genetics of capsular polysaccharide production in bacteria. Annu Rev Microbiol 50: 285–315
3. Marino K, Bones J, Kattla JJ et al (2010) A systematic approach to protein glycosylation analysis: a path through the maze. Nat Chem Biol 6:713–723
4. Kadioglu A, Weiser JN, Paton JC et al (2008) The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 6:288–301
5. Avci FY, Kasper DL (2010) How bacterial carbohydrates influence the adaptive immune system. Annu Rev Immunol 28:107–130
6. Cobb BA, Kasper DL (2005) Coming of age: carbohydrates and immunity. Eur J Immunol 35:352–356
7. Francis T, Tillett WS (1930) Cutaneous reactions in pneumonia. The development of antibodies following the intradermal injection of type-specific polysaccharide. J Exp Med 52:573–585
8. Schumann B, Anish C, Pereira CL et al (2014) Chemical biology approaches to designing defined carbohydrate vaccines. Chem Biol 21:38–50
9. Medzhitov R, Janeway CA Jr. (1997) Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 9:4–9
10. Palm NW, Medzhitov R (2009) Pattern recognition receptors and control of adaptive immunity. Immunol Rev 227:221–233
11. Cruvinel WD, Mesquita D, Araujo JAP et al (2010) Immune system—Part I Fundamentals of innate immunity with emphasis on molecular and cellular mechanisms of inflammatory response. Rev Bras Reumatol 50:434–461
12. Kapsenberg ML (2003) Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 3:984–993
13. Romagnani S (2000) T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol 85:9–21
14. Zhu J, Yamane H, Paul WE (2010) Differentiation of Effector CD4 T Cell Populations. Annu Rev Immunol 28:445–489
15. O’Connor W, Zenewicz LA, Flavell RA (2010) The dual nature of TH17 cells: shifting the focus to function. Nat Immunol 11:471–476
16. Singh RP, Hasan S, Sharma S et al (2014) Th17 cells in inflammation and autoimmunity. Autoimmun Rev 13:1174–1181
17. Crotty S (2011) Follicular Helper CD4 T Cells (TFH). Annu Rev Immunol 29:621–663
18. Parker DC (1993) T cell-dependent B cell activation. Annu Rev Immunol 11:331–360
19. Murphy K, Travers P, Walport M, Janeway CA (2012) Janeway’s immunobiology. Garland Science, New York
20. Guttormsen H-K, Sharpe AH, Chandraker AK et al (1999) Cognate stimulatory B-cell–T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect Immun 67:6375–6384
21. Mond JJ, Lees A, Snapper CM (1995) T cellindependent antigens type 2. Annu Rev Immunol 13:655–692
22. Landers C, Chelvarajan RL, Bondada S (2005) The role of B cells and accessory cells in the neonatal response to TI-2 antigens. Immunol Res 31:25–36
23. Weintraub A (2003) Immunology of bacterial polysaccharide antigens. Carbohydr Res 338: 2539–2547
24. Vos Q, Lees A, Wu ZQ et al (2000) B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev 176:154–170
25. López-Herrera G, Vargas-Hernández A, González-Serrano ME et al (2014) Bruton’s tyrosine kinase—an integral protein of B cell development that also has an essential role in the innate immune system. J Leukoc Biol 95:243–250
26. Bondada S, Chelvarajan RL (2004) Neonatal immunity to polysaccharide antigens: role of B cells versus macrophages. Nat Rev Immunol. doi: 10.1038/nri1394-c1
27. Velez CD, Lewis CJ, Kasper DL et al (2009) Type I Streptococcus pneumoniae carbohydrate utilizes a nitric oxide and MHC II-dependent pathway for antigen presentation. Immunology 127:73–82
28. Avci FY, Li X, Tsuji M et al (2013) Carbohydrates and T cells: a sweet twosome. Semin Immunol 25:146–151
29. Vinuesa CG, Chang P-P (2013) Innate B cell helpers reveal novel types of antibody responses. Nat Immunol 14:119–126
30. Alugupalli KR, Akira S, Lien E et al (2007) MyD88- and Bruton’s tyrosine kinasemediated signals are essential for T cellindependent pathogen-specific IgM responses. J Immunol 178:3740–3749
31. Dagan R, Poolman J, Siegrist C-A (2010) Glycoconjugate vaccines and immune interference: a review. Vaccine 28:5513–5523
32. Adamo R, Nilo A, Castagner B et al (2013) Synthetically defined glycoprotein vaccines: current status and future directions. Chem Sci 4:2995–3008
33. Pobre K, Tashani M, Ridda I et al (2014) Carrier priming or suppression: understanding carrier priming enhancement of antipolysaccharide antibody response to conjugate vaccines. Vaccine 32:1423–1430
34. Lucas AH, Apicella MA, Taylor CE (2005) Carbohydrate moieties as vaccine candidates. Clin Infect Dis 41:705–712
35. Avci FY, Li X, Tsuji M et al (2011) A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med 17: 1602–1609
36. Kuberan B, Lindhardt RJ (2000) Carbohydrate based vaccines. Curr Org Chem 4:653–677
37. Astronomo RD, Burton DR (2010) Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 9:308–324
38. Makela PH (2003) Conjugate vaccines-a breakthrough in vaccine development. Southeast Asian J Trop Med Public Health 34:249–253
39. Irving TJ, Blyuss KB, Colijn C et al (2012) Modelling meningococcal meningitis in the African meningitis belt. Epidemiol Infect 140:897–905
40. Cohn A, Harrison L (2013) Meningococcal vaccines: current issues and future strategies. Drugs 73:1147–1155
41. Hedari CP, Khinkarly RW, Dbaibo GS (2014) Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease. Infect Drug Resist 7:85–99
42. Daugla DM, Gami JP, Gamougam K et al (2014) Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet 383:40–47
43. Arguedas A, Soley C, Abdelnour A (2011) Prevenar experience. Vaccine 29:C26–C34
44. Prymula R, Schuerman L (2009) 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix™. Expert Rev Vaccines 8:1479–1500
45. Gruber WC, Scott DA, Emini EA (2012) Development and clinical evaluation of Prevnar 13, a 13-valent pneumococcal CRM197 conjugate vaccine. Ann NY Acad Sci 1263:15–26
46. Alving CR, Peachman KK, Rao M et al (2012) Adjuvants for human vaccines. Curr Opin Immunol 24:310–315
47. Marrack P, McKee AS, Munks MW (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9: 287–293
48. Rappuoli R, Mandl CW, Black S et al (2011) Vaccines for the twenty-first century society. Nat Rev Immunol 11:865–872
49. De Gregorio E, Tritto E, Rappuoli R (2008) Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 38:2068–2071
50. Eisenbarth SC, Colegio OR, O’Connor W et al (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453:1122–1126
51. Dostert C, Ludigs K, Guarda G (2013) Innate and adaptive effects of inflammasomes on T cell responses. Curr Opin Immunol 25:359–365
52. Mohan T, Verma P, Rao D (2013) Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res 138:779–795
53. Mbow ML, De Gregorio E, Valiante NM et al (2010) New adjuvants for human vaccines. Curr Opin Immunol 22:411–416
54. Awate S, Babiuk LA, Mutwiri G (2013) Mechanisms of action of adjuvants. Front Immunol. doi: 10.3389/fimmu.2013.00114
55. Duthie MS, Windish HP, Fox CB et al (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239:178–196
56. Lang R, Schoenen H, Desel C (2011) Targeting Syk-Card9-activating C-type lectin receptors by vaccine adjuvants: Findings, implications and open questions. Immunobiology 216:1184–1191
57. Janeway CA, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197–216
58. Cummings RD, McEver RP (2009) C-type lectins. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME (eds) Essentials of glycobiology, 2nd edn. Cold Spring Harbor, New York, NY
59. Sancho D, Reis e Sousa C (2012) Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol 30:491–529
60. Geijtenbeek TBH, Gringhuis SI (2009) Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 9:465–479
61. van Kooyk Y, Geijtenbeek TBH (2003) DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol 3:697–709
62. Drummond RA, Brown GD (2013) Signalling C-type lectins in antimicrobial immunity. PLoS Pathog 9, e1003417
63. Lepenies B, Lee J, Sonkaria S (2013) Targeting C-type lectin receptors with multivalent carbohydrate ligands. Adv Drug Deliv Rev 65: 1271–1281
64. Drickamer K (1992) Engineering galactosebinding activity into a C-type mannosebinding protein. Nature 360:183–186
65. van Kooyk Y, Unger WWJ, Fehres CM et al (2013) Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation. Mol Immunol 55:143–145
66. Miyake Y, Toyonaga K, Mori D et al (2013) C-type lectin MCL is an FcRγ-coupled receptor that mediates the adjuvanticity of mycobacterial cord factor. Immunity 38:1050–1062
67. Carvalho A, Giovannini G, De Luca A et al (2012) Dectin-1 isoforms contribute to distinct Th1/Th17 cell activation in mucosal candidiasis. Cell Mol Immunol 9:276–286
68. Petrovsky N, Cooper PD (2011) Carbohydratebased immune adjuvants. Expert Rev Vaccines 10:523–537
69. Egli A, Santer D, Barakat K et al (2014) Vaccine adjuvants—understanding molecular mechanisms to improve vaccines. Swiss Med Wkly 144:w13940
70. Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4:499–511
71. Zughaier SM (2011) Neisseria meningitidis capsular polysaccharides induce inflammatory responses via TLR2 and TLR4-MD-2. J Leukoc Biol 89:469–480
72. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783–801
73. Park BS, Lee J-O (2013) Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp Mol Med 45, e66
74. Petrovsky N, Aguilar JC (2004) Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82:488–496
75. Gordon DL, Sajkov D, Woodman RJ et al (2012) Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant. Vaccine 30: 5407–5416
76. Cooper PD, Petrovsky N (2011) Delta inulin: a novel, immunologically active, stable packing structure comprising β-d-[2 → 1] poly(fructofuranosyl) α-d-glucose polymers. Glycobiology 21:595–606
77. Lamkanfi M, Malireddi RKS, Kanneganti T-D (2009) Fungal zymosan and mannan activate the cryopyrin inflammasome. J Biol Chem 284:20574–20581
78. Fernández-Tejada A, Chea EK, George C et al (2014) Development of a minimal saponin vaccine adjuvant based on QS-21. Nat Chem 6:635–643
79. Marciani DJ (2003) Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 8:934–943
80. Ragupathi G, Gardner JR, Livingston PO et al (2011) Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev Vaccines 10:463–470
81. Agnandji ST, Fendel R, Mestré M et al (2011) Induction of plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS, S/AS01(E) and RTS, S/AS02(D). PLoS One 6, e18559